search

Active clinical trials for "Prostatic Hyperplasia"

Results 161-170 of 588

Assessing Safety & Efficacy of MediTate Temporary Implant in Subjects With Benign Prostate Hyperplasia...

Bladder Neck ObstructionBenign Prostate Hyperplasia

The purpose of this study is to assess the safety and efficacy of MediTate Temporary Implantable Nitinol Device (TIND) used to alleviate symptoms of Bladder Outlet Obstruction (BOO) secondary to Benign Prostate Hyperplasia (BPH).The TIND is inserted in the bladder neck and prostatic urethra under local anesthesia for few days and taken out some 5 days later in the doctors office.

Completed21 enrollment criteria

TRADE-Testosterone Replacement and Dutasteride Effectiveness

HypogonadismBenign Prostatic Hyperplasia

The purpose of this research study is to determine whether the combination of the male hormone testosterone [T] in gel form and the oral drug dutasteride [D], used to shrink large prostate glands can safely reduce the size of the prostate gland and symptoms of prostate enlargement (called benign prostatic hyperplasia [BPH]) compared to T treatment alone in men with low testosterone (called hypogonadism).

Completed25 enrollment criteria

Bipolar vs Monopolar Transurethral Resection of the Prostate (TURP)

BPHBenign Prostatic Hyperplasia

This study will prospectively evaluate a new electrosurgical procedure (bipolar transurethral prostatectomy) in men with symptomatic benign prostatic hyperplasia.

Completed13 enrollment criteria

The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months

Benign Prostatic Hyperplasia

A new drug for benign prostatic hyperplasia is used for 9 months to determine its long-term safety.

Completed5 enrollment criteria

Effect Of Dutasteride On Intraprostatic Dihydrotestosterone (DHT) Levels

Prostatic Hyperplasia

This study is being done to determine how much certain hormone levels in the prostate decrease when a patient takes dutasteride 0.5mg daily for 3 months prior to TURP. Male patients at least 50 years old willing to take either dutasteride or a placebo (dummy pill) once daily by mouth for 3 months prior to having a surgery to reduce the size of their prostate. During the surgery, very small pieces of the prostate that are removed will be tested to see how much dihydrotestosterone and testosterone (male hormones) are in the tissue.

Completed8 enrollment criteria

A Study of an Investigational Study Drug for Benign Prostatic Hyperplasia (0906-140)

Benign Prostatic Hyperplasia

The purpose of this trial is to determine the efficacy and safety of an investigational drug in patients with benign prostatic hyperplasia.

Completed2 enrollment criteria

Effectiveness of a Treatment Protocol for Lower Urinary Tract Symptoms in General Practice

Benign Prostatic HyperplasiaLower Urinary Tract Symptoms

Ageing and the availability of medication has led to an increase of elderly male patients being treated for lower urinary tract symptoms (LUTS), or voiding problems ("prostate problems"). However, guidelines are vague as to which patients should and which should not be treated, and how. Although several treatment modalities have proven efficacy in selected populations, it is unclear how effective these treatments are in daily practice. This study investigates the hypothesis that a treatment protocol in which clear indications are formulated for all treatment modalities is more effective, as compared to current usual primary care, in reducing both symptoms as related to the quality of voiding in elderly males.

Completed7 enrollment criteria

Dose Escalation Study With QLT0074 for Benign Prostatic Hyperplasia

Benign Prostatic Hyperplasia

The primary objective of this study is to assess the safety and tolerance of transurethral photodynamic therapy (PDT) with QLT0074. Secondary objectives are: To determine if transurethral PDT with QLT0074 has a therapeutic effect on benign prostatic hyperplasia (BPH), evaluated by the American Urological Association Symptom Index (AUA SI), urinary flow rate (Qmax), and post-void residual volume (PVR). To determine the extent of systemic exposure to QLT0074 following transurethral intraprostatic injection. To select up to two transurethral PDT drug-light regimens for further clinical development.

Completed2 enrollment criteria

Clinical Results of Odyliresin (Iresine Celosia) in Symptomatic Benign Prostatic Hyperplasia

Benign Prostatic Hypertrophy With Outflow ObstructionBenign Prostatic Hyperplasia

Odyliresin (Iresine Celosia) is a cytochrome-flavoprotein with a powerful anti-oxydant action on cells, has a therapeutic effect on BPH-related LUTS, reducing symptoms, prostate volume, improving the patient's quality of life and eventually limiting the number of patients who require surgery or endoscopy after medical treatment.

Completed9 enrollment criteria

Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic...

Benign Prostatic Hyperplasia

A single-arm prospective, interventional clinical trial to evaluate the safety and performance of obtaining hemostasis with commercially approved catheters following prostate resection using the AquaBeam for treatment of LUTS resulting from BPH.

Completed2 enrollment criteria
1...161718...59

Need Help? Contact our team!


We'll reach out to this number within 24 hrs